XSHE
002868
Market cap513mUSD
Oct 09, Last price
22.10CNY
1D
-0.05%
1Q
-9.35%
IPO
26.53%
Name
Lifecome Biochemistry Co Ltd
Chart & performance
P/E
—
P/S
6.65
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.20%
Rev. gr., 5y
7.29%
Revenues
517m
-20.45%
Net income
-139m
L-68.70%
CFO
-25m
L
Dividend
May 21, 20210.14 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical enterprise within China. The company's diverse product portfolio includes bacitracin zinc, colistin sulfate, probiotics, and bacitracin methylene disalicylate products. It also provides biological preservatives and natamycin. Established in 2003, the firm maintains its base of operations in Pucheng, China.
Key people
Zuan Wang
Chairman of the Board · since 2025
Zhongshou Bao
Chief Financial Officer · since 2025
Jing Yang
Acting General Manager, Deputy General Manager, Director · since 2025
Hui Huang
Deputy General Manager · since 2017
Junhui Li
Deputy General Manager · since 2017
Xinhong Lin
Secretary of the Board · since 2025
Shiping Jiang
Staff Elected Director · since 2025
Tanping Lai
Director · since 2025
Independent Director · since 2025
Independent Director · since 2025
Headquarters & legal address
福建省南平市浦城县园区大道6号
南平市, FJ 353400
CN
南平市, FJ 353400
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||